SoundCure Launches the Serenade® Tinnitus Treatment System with FDA Clearance and CE Mark
New customized sound therapy approach with novel treatment sounds
SAN JOSE, California, March 26, 2012. SoundCure Inc., a new tinnitus solution provider, today announced the launch of the Serenade Tinnitus Treatment System at the upcoming American Academy of Audiology Meeting in Boston, March 28 – April 1, 2012. This marks the formal commercial release of a novel advancement in sound therapy based on the development of S-Tones®, customized treatment sounds developed independently by leading hearing researchers at the University of California, Irvine (UCI).
Tinnitus, or “ringing in the ears”, affects approximately 10% of U.S. adults and an estimated 260 million people globally. It can be extremely debilitating, leading to depression, irritability, and difficulty sleeping or concentrating. It is most often related to hearing loss, especially that caused by noise damage.
Serenade is a handheld device that is programmed in the audiologist’s office for each individual patient according to his specific condition. Through the device’s earphones, the patient listens to therapeutic sounds which are designed to address the underlying neurological cause of tinnitus. Four different treatment sounds are available, anchored by advanced, proprietary S-Tones. Long-term relief can be achieved when used in an on-going sound therapy program.
The American Tinnitus Association provided a grant to UCI to develop the technology. Sound therapy as a tinnitus treatment is well-established and effective. S-Tones are low frequency, amplitude modulated tones that are frequency pitch-matched to a patient’s unique tinnitus, representing a significant clinical breakthrough compared to previous approaches. According to Dr. Fan-Gang Zeng, one of the technology inventors, these modulated tones “keep the brain’s interest” thus “inhibiting and reducing the perceived tinnitus sound and bringing relief”. In addition, S-Tones are intended to be “listened to at a volume that is lower than the patient’s tinnitus, reducing the sound burden”, according to Dr. Zeng.
SoundCure CEO Bill Perry states, “This approach was developed by a team with a deep scientific understanding of the neurophysiology of tinnitus and how the brain processes sound. It is an important solution to provide relief to patients and represents a real advance in tinnitus care.”
About SoundCure, Inc.
Established in 2009 to commercialize the technology developed for years at the University of California, Irvine, SoundCure, Inc. is a privately held medical device company whose mission is to revolutionize the treatment of tinnitus and provide relief to the millions of people suffering its effects. SoundCure is an Allied Minds company.